secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0000885725-24-000078
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market
--------------------------------------------------------------------------------

- Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.
- Deal expected to be immaterial to adjusted EPS in 2024-2025, accretive thereafter.
- Adds Axonics' sacral neuromodulation portfolio for urinary/bowel dysfunction to Urology unit.
- GAAP basis less accretive due to amortization and acquisition-related charges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000078/0000885725-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000078/bsx-20241115.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer